Drug Trial Radar · NCT07624513
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Oct 1, 2033
Study completion Mar 1, 2038
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi; Bristol-Myers Squibb; Celgene Corporation; Regeneron Pharmaceuticals
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment. The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits. It is expected that about 720 participants will take part in this study.
Conditions
- Multiple Myeloma
Interventions
IsatuximabDrug
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
IberdomideDrug
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Bortezomib (B)Drug
Commercial supply; used in induction and Arm G maintenance; administered subcutaneously in Arm G on Days 1 and 15 of each 28-day cycle.
DexamethasoneDrug
Commercial supply; used in induction; may be administered intravenously or orally at investigator discretion; excluded from Arm G.
MelphalanDrug
Commercial supply; used as conditioning therapy for Arm E before PBSC infusion/ASCT; administered intravenously.
LinvoseltamabDrug
Supplied by Regeneron; used in Arm F consolidation for 8 cycles before maintenance therapy.
On Body Delivery System (OBDS)Device
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-Year Sustained Minimal Residual Disease (sMRD)-negative Complete Response (CR) Rate [Cohort 1] (Step 2)Time frame: Assessed after Step 2 maintenance cycle 36 (cycle duration=4 weeks), at 144 weeks/36 months.
- 1-Year MRD-Negative CR Rate [Cohort 2] (Step 2)Time frame: Assessed 1-year after Step 2 consolidation randomization.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts · Not yet recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.